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BACKGROUND: Ethiopia has pledged to the UNAIDS 90-90-90 
framework. However, the achievements of these UNAIDS targets 
are not assessed in Southwest Ethiopia. Using HIV care and 
treatment outcomes as surrogate markers, we assessed all targets. 
METHODS: Complex surrogate makers were used to assess the 
HIV care continuum outcomes using antiretroviral therapy data in 
Jimma University Teaching Hospital. Early HIV diagnosis was a 
surrogate marker to measure the first 90. Numbers of people on 
HIV treatment and who have good adherence were used to 
measure the second 90. To measure the third 90, we used 
immunological success that was measured using numbers of CD4 
counts, clinical success using WHO clinical stages and treatment 
success using immunological and clinical successes.  
RESULTS: In total, 8172 patients were enrolled for HIV care from 
June 2003 to March 2015. For the diagnosis target, the prevalence 
of early HIV diagnosis among patients on ART was 35% (43% 
among children and 33.3% among adults). For the treatment 
target, 5299(65%) received ART of which 1154(22%) patients lost 
to follow-up or defaulted from ART treatment, and 1015(19%) 
patients on treatment transferred out to other sites. In addition, 
17% had fair or good adherence. Finally, 81% had immunological 
success, 80% had clinical success and 66% treatment success. 
CONCLUSIONS: The study revealed that Southwest Ethiopia 
achieved 35%, 65% and 66% of the first, second and third 
UNAIDS targets, a very far performance from achieving the target. 
These highlight further rigorous interventions to improve outcome 
of HIV continuum of care.  
KEYWORDS: UNAIDS 90-90-90, HIV care continuum, early HIV 




The Joint United Nations Program on HIV and AIDS (UNAIDS) (1) 
and partners proposed three targets by 2020 (2). These include (i) 
diagnosing 90% of the total number of people living with HIV (first 
90), (ii) delivering antiretroviral therapy (ART) to 90% of those 
diagnosed or 81% of total number HIV positive people (second 90), 
and attaining viral suppression for 90% of patients getting treatment 
or 73% of the total number HIV positive people (third 90).  
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The effectiveness of ART program of a country relies 
on the series of steps a person with HIV takes from 
diagnosis to successful HIV treatment, and this 
cascade is named as HIV care continuum (HCC)(3). 
HCC comprises HIV testing and diagnosis, screening 
for eligibility of ART, lifelong retention in the care, 
and clinical and immunologic successes and 
virological suppression through ART compliance 
adherence. Several factors affect the success of each 
step of the cascade, and this in turn, will make the 
success of the ambitious 90-90-90 targets 
challenging(3, 4).  
Since the inception of the targets in 2014, few 
estimates have been reported about the progress, and 
no country has achieved these targets except Sweden. 
For the HIV diagnosis target, Sweden was reported to 
have achieved 90% whereas Yemen has achieved 
only 11% (2). For the treatment target, Sweden 
attained 97.1% followed by Switzerland (71%) 
whereas Yemen and Afghanistan attained 3% each 
respectively (2). Sweden, Switzerland, Australia, 
USA and Russia  recorded 95%, 68%, 62%, 30% and 
9% virological suppression respectively (2). 
Botswana found overall coverage levels that nearly 
achieved the UNAIDS target(5).  
Ethiopia is a low-income country with an HIV 
prevalence of 0.9% in 2016 (6). ART program was 
initially started in 2003 in 12 hospitals where patients 
pay for the treatment (7), but the program was 
provided for free in 22 hospitals since 2005 with aid 
from the Global Fund, World Bank, and PEPFAR (8). 
As a result, 535,069 people with HIV ‘ever started’ 
ART in more than 1000 health centers and hospitals 
in 2015(9). Ethiopia, like other countries in SSA, has 
subscribed to the UNAIDS 90-90-90 targets  (10). 
However, no assessment was conducted about the 
progress. The current study investigated HIV care 
cascade outcomes as surrogates for the 90-90-90 
targets using 12 years’ retrospective data from Jimma 




Study design, study setting and study participants: 
A retrospective cohort study was undertaken in 
Jimma University Teaching Hospital (JUTH) ART 
clinic, Jimma, Southwest Ethiopia. The data covered 
from 21 June 2003 to 15 March 2015. Jimma Town is 
the capital city of Jimma Zone in Oromia Region, and 
this region had the highest number of HIV cases in 
the country. Jimma is also located near Gambella 
Region which had the highest HIV prevalence rate 
(6.5%) in Ethiopia (11). Furthermore, near Jimma 
Town, there is a refugee camp with a number of 
refugees from different African countries; this 
increases the risk of HIV in the area, as observed in 
other areas (12).  
JUTH provides several HIV services including 
voluntary counseling and testing (VCT), prevention 
of mother to child transmission (PMTCT), provider-
initiated HIV testing and counseling (PITC), ART 
and treatment for opportunistic infections (OIs) since 
2003. From 2015 to mid 2016, according to the 
national (13) and WHO (14) guidelines, HIV infected 
people are eligible to ART if their CD4 counts is  
below 500 cells/µl irrespective of WHO clinical stage 
or WHO clinical stage is 3 or 4 irrespective of CD4 
counts. All Tuberculosis patients, children, pregnant 
and breast-feeding mothers are eligible for ART in 
spite of CD4 count or WHO clinical stage. However, 
since the end of 2016, Ethiopia has started ‘test and 
treat’ strategy where every HIV positive person starts 
the treatment although this is yet to be rolled out all 
over the country (15).   
 
Table 1: Ideal measure and surrogate markers for UNAIDS 90-90-90 targets, 2016.  
UNAIDS Target* Ideal measure Surrogate measures 
1 Number of HIV infected 
individuals aware of their 
HIV status  
Number of patients with delayed HIV diagnosis 
2 Number of HIV infected 
population receiving ART 
Number of HIV infected population on ART, number of 
discontinued, number of patients with fair/poor adherence 
3 Number of patients with 
undetected viral count 
copies/mL)  
Number of patients with immunological, clinical and treatment 
success 
*Target 1 (HIV diagnosis): 90% of patients knowing their status; Target 2 (HIV treatment): 90% of diagnosed 
patients receiving treatment; Target 3 (virological suppression): 90% of patients on antiretroviral therapy (ART) 
achieving viral suppression 
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Measurements: Table 1 presents the complex 
surrogate makers/indicators which were used to 
assess the HIV care continuum outcomes and further 
show an overall proxy surrogate for UNAIDS targets.  
To measure the diagnosis target, delayed HIV 
diagnosis (DHD) was considered as a surrogate 
marker. DHD reflects that people are suspicious of 
their HIV status before diagnosis but late for knowing 
their HIV status(16). To measure the treatment target, 
the number of people on ART out of those diagnosed 
was used as a surrogate marker. In addition, to assess 
whether the treatment intake was sustainable or not, 
number of people who were lost to follow-up or had 
defaulted (had discontinued) or transferred out, and 
number of people who had fair or poor ART 
compliance were considered. For measuring the viral 
suppression target, we used number of CD4 counts to 
assess immunological success and WHO clinical 
stages to assess clinical success. Treatment success, 
measured by the rate of immunological and clinical 
successes, was used as a final surrogate measure to 
increase the probability of estimating viral 
suppression. The measurement for ART 
discontinuation was published elsewhere (17). The 
operational definitions for delayed HIV diagnosis 
(late presentation for HIV care), ART adherence, and 
immunological, clinical and treatment successes are 
published elsewhere(18). 
Data source and procedures: The data in ART 
clinic in JUTH is stored in a database center called 
the comprehensive care center patient application 
database (C-PAD). The C-PAD is an electronic 
medical records (EMR) system and uses the 
Structured Query Language (SQL) format. The 
database was designed in 2007 and has been 
functional since then. The data entry process is 
undertaken by two data clerks and this ensures data 
completeness, accuracy and reliability. In addition, 
the International Center for AIDS Care and 
Support (ICAP) at Colombia University delivered 
technical assistance on the data management 
system. We excluded records with no baseline CD4 
count and WHO clinical stage, and ART start date 
during the analysis of DHD. Similarly, for the 
analysis of immunological and clinical successes, 
we excluded records with no record of CD4 count 
and WHO clinical stage at baseline and after six 
months.  
Data analyses: Data were edited, explored and 
cleaned before analysis. Descriptive statistics was 
performed to describe study population 
characteristics and produce summary statistics. We 
used proportions and percentages for categorical 
data, and for continuous data, we used mean, 
median, range and line graphs. Eleven years trends 
for DHD, discontinuation and immunologic failure 
for patients on ART were described by line graphs. 
We excluded data for years 2003 and 2015 while 
producing line graph as the number of months in 
both years are incomplete. For each graph, we 
developed a best-fit equation for the trend line, and 
shown in the graph if R2 is above 75%. Estimated 
survival time for children and adults was calculated 
using Kaplan-Meier. We performed the data 
analysis using Statistical Package for the Social 
Sciences (SPSS) 22.0.  
Ethical statement: The study was approved by 
Social and Behavioral Research Ethics Committee 
(SBREC) at Flinders University (Project number: 
7086) and Institutional Review Board (IRB) of 
College of Health Sciences at Jimma University 
(Ref No: RPGC/386/2016). The data access 
permission was obtained from JUTH board. We did 
not involve any participant in this study, we only 




Characteristics of cohort: From the available 
ART data, 5,299 out of 8,172 available patients 
(64.8%) were on ART, and the remaining included: 
eligible and ready for ART (0.1%), eligible for 
ART (0.2%) and on pre-ART (34.9%). There were 
399 (7.5%) children and 4900 (92.5%) adults 
registered for ART. Table 2 depicts the 
characteristics (clinical and non-clinical) of the 
study participants.  
Southwest Ethiopia cascade of the UNAIDS 90-
90-90 targets: Figure 1 presents the Ethiopian 
cascade of the UNAIDS 90-90-90 Targets, and are 
reported in detail as follows. 
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Table 2: Clinical and non-clinical characteristics of HIV infected people enrolled in ART care in Southwest Ethiopia 
from 2003 to 2015.  
Variable Children (N=399), N (%) Adult (N=4900), N (%) 
Age in years 
 
<1 21(5.3) ---------- 
1-<5 146(36.6) ---------- 
5-<15 232(58.1) ---------- 
15-<25 ---------- 711(14.5) 
25-<50 ---------- 3937(80.3) 
50+ ---------- 252(5.2) 
Median (range)  6(<1-14) 30(15-81) 
ART follow up time in months, median (range) 40 (0-116) 49(0-137) 
Estimated survival time, months, median (95%CI) 
Sex                                  Male 







Marital status b  Never married ---------- 897(20.9) 
Married ---------- 2094(48.7) 
Separated/divorced/widowed  ---------- 1311(30.5) 
Education b No education  ---------- 945(21.9) 
Primary ---------- 1687(39.1) 
Secondary and above ---------- 1685(39) 
Religion b Muslim 47(26.1) 1402(32.6) 
Christiana  133(73.9) 2893(67.4) 
Baseline WHO 
classification b 
1 or 2 108(49.5) 1355(45.7) 
3 or 4 110(50.5) 1608(54.3) 
Baseline CD4 count 
category b 




Median (range) CD4 count 282(0-2250) ---------- 
Baseline CD4 count 
(cells/mm3) b 
<200  ---------- 3275(73.6) 
≥ 200  ---------- 1174(26.4) 
Median (range)  156(0-1313) 
History of Tb/HIV 
co-infection b 
No 285(71.4) 3533(72.1) 
Yes 114(28.6) 1367(27.9) 
ARV adherence b Good 319(79.9) 4064(82.9) 
Fair or poor 80(20.1) 836(17.1) 
Cotrimoxazole 
adherence b 
Good 315(78.9) 4119(94.4) 
Fair or poor 84(21.1) 762(15.6) 
Hx of HIV testing b Yes 399(100) 2860(58.4) 
No 0(0) 2040(41.6) 
ART shift b No 214(97.7) 3190(99.1) 
Yes 5(2.3) 29(0.9) 
Baseline functional 
status b 
Appropriate 170(42.6) ---------- 
Delay or regression 229(57.4) ---------- 
Baseline functional 
status b 
Work or Ambulatory ---------- 3064(68.1) 
Bedridden ---------- 1437(31.9) 
Timing to HIV 
diagnosis 
Early 162(43) 894(33.3) 
Late 215(57) 1788(66.7) 
Clinical failure b No 165(77.1) 2261(80.5) 
Yes 49(22.9) 546(19.5) 
Immunologic failure b No 295(84.8) 3164(80.3) 
Yes 53(15.2) 775(19.7) 
 
Treatment failure b 
No 126(67.4) 1493(65.7) 
Yes 61(32.6) 780(34.3) 
a Orthodox, Catholic, Protestant; b only valid percentage is calculated; ARV=antiretroviral therapy  
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Figure 1: Southwest Ethiopia cascade of the UNAIDS 90-90-90 Targets, 2016 
 
UNAIDS target 1-diagnosis target: Overall, 
65.5% of the patients were deemed DHD in which 
females accounted for 64.3%. This indicates that 
only 34.5% of the patients knew their status timely 
(females contributed for 35.7%). When it was 
analyzed by age, the prevalence of DHD was 57% 
among children and 66.7% among adults. The 
analysis of DHD showed slightly upward trends 




Figure 2: Trends in the percentage distribution of late presentation for HIV care among HIV infected 
people on ART, Southwest Ethiopia, 2004-2014 
NB. The thin black in the graph shows the predicted equation for the trend of late presentation for HIV care 
displayed in the graph using thick blue line. 
 
UNAIDS target-ART treatment target: Out of 
the 8,172 individuals who were diagnosed with 
HIV infection and enrolled for HIV care, 5,299 
(65%) patients received ART. Of those enrolled in 
ART, 1154(21.9%) patients discontinued the 
treatment (females accounted for 54.8%). 
Additionally, 1015(19.3%) patients transferred out 
(TO) to other sites, and of these, females accounted 
for 54.6%. A total of 228(4%) and 688(13%) 
patients had fair and poor adherence respectively. 
The significant rate of ART discontinuation, TO 
and ART non-adherence indicates that the 
treatment was not provided sustainably. 
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challenge and its trend in the recent years was 
rising (Figure 3). Table 3 demonstrates yearly 
number of patients enrolled in HIV care and 




Figure 3: Trends in the percentage distribution of discontinuation from ART among HIV infected people on 
ART, Southwest Ethiopia, 2004-2014 
NB. The thin black in the graph shows the predicted equation for the trend of discontinuation from ART 
displayed in the graph using thick blue line. 
 
UNAIDS target 3-Viral suppression target: In 
total, 80.7% had immunological success, 80.3% 
had clinical success and 65.8% of patients had 
treatment success. This depicts that at least an 
estimated 66% of patients achieved viral 
suppression. The trend of immunologic failure has 
been increasing in the recent years (Table 3), 
indicating that the trend of immunologic success is 
deteriorating.
Table 3. Annual number of patients enrolled in ART care and their outcomes 
 
a Data for years 2003 and 2015 were not from complete number of months and were excluded from trend graph. 
e = f-b-c-d; where f = e (previous year) +  a (current year) 





























Outcome final, n (%) Immunologic status, n (%) 










2003a 8 0(0) 1(12.5) 0(0) 7(87.5) 8 5(100) 0(0) 
2004 62 1(1.4) 7(10.1) 1(1.4) 60(87.0) 69 17(68) 8(32) 
2005 484 28(5.1) 51(9.4) 9(1.7) 456(83.8) 544 301(78.2) 84(21.8) 
2006 973 66(4.6) 90(6.3) 71(5.0) 1202(84.1) 1429 911(77.3) 267(22.7) 
2007 622 53(2.9) 155(8.5) 137(7.5) 1479(81.1) 1824 1333(78.8) 358(21.2) 
2008 555 45(2.2) 112(5.5) 97(4.8) 1780(87.5) 2034 1698(79.4) 441(20.6) 
2009 566 42(1.8) 54(2.3) 109(4.6) 2141(91.3) 2346 2077(79.3) 543(20.7) 
2010 481 23(0.9) 152(5.8) 81(3.1) 2366(90.2) 2622 2429(79.9) 610(20.1) 
2011 461 29(1.0) 93(3.3) 112(4.0) 2593(91.7) 2827 2778(80.8) 659(19.2) 
2012 383 11(0.4) 101(3.4) 103(3.5) 2761(92.8) 2976 3048(81) 714(19) 
2013 324 17(0.6) 117(3.8) 107(3.5) 2844(92.2) 3085 3247(80.8) 770(19.2) 
2014 320 9(0.3) 179(5.7) 158(5.0) 2818(89.1) 3164 3428(80.7) 822(19.3) 
2015a 60 2(0.1) 42(1.5) 30(1.0) 2763(97.4) 2878 3459(80.7) 828(19.3) 
Overall  326(6.2) 1154(21.9) 1015(19.3) 2763(52.5) 5299 3459(80.7) 828(19.3) 
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This study was conducted to assess HIV care 
continuum outcomes in each cascade and provide 
important insights about the progress of the 
UNAIDS 90-90-90 targets in Ethiopia. There were 
high prevalence rates of DHD, ART 
discontinuation, non-adherence, and 
immunological, clinical and treatment failures. 
High prevalence rate of DHD implies that a 
number of people did not know their HIV status. In 
the current study, only 35% of patients knew their 
status timely, a very low performance compared 
with the UNAIDS target and the 45% performance 
by SSA(19) . Additionally, about 40% (3225/8172) 
of participants did not have a history of HIV testing 
before diagnosis in the current study. As reflected 
in the findings, only 65% of people diagnosed with 
HIV infection were receiving ART. Even among 
those who were receiving ART, 22% of them had 
discontinued the treatment, 19% had been 
transferred out to other ART sites, and 17% had 
fair or poor ART adherence. These indicate that a 
considerable number of patients were not receiving 
ART sustainably. This is lesser than the target set 
by UNAIDS, and the findings from SSA (19) 
reporting 86% achievement.  
Given that the access for Plasma HIV-1 RNA 
(viral load) monitoring is very limited and is not 
available for routine services in Ethiopia, treatment 
successes was used as a surrogate marker for the 
virological suppression. Accordingly, 66% of 
patients on ART showed treatment success 
reflecting achieved viral suppression. This 
performance is also lower than the UNAIDS target, 
and the 76% achievement by SSA (19). Evidence 
shows(20) have shown that number of CD4 count 
determines virological failure or suppression unlike 
some others that reported the reverse(21).  
In the current study, compared to males, 
females had high proportion of DHD, 
discontinuation from ART, and immunological, 
clinical and treatment failures. This could be 
attributed to a variety of reasons including: (i) high 
levels of stigma in females which may deter them 
from HIV care seeking (22), and (ii) given that 
females are living in a male dominated society in 
Ethiopia, they face barriers (23) to  accessing HIV 
care, and (iii) the implementation of integrated 
modern and traditional medicine in Ethiopia is 
limited, and patients could not attend the care 
timely and sustainably (24). 
To reduce DHD, the use of technology is one 
of the recommended strategies. Amukele and 
colleagues’ study showed that Malawi is piloting 
drones for transporting laboratory specimens to 
improve early HIV diagnosis in infant with the aid 
of UNICEF(25). Furthermore, community-based 
HIV testing (26), mobile text messages (27) and 
home-based HIV testing (28) are also other 
recommended programs to meet the first UNAIDS 
target via overcoming DHD. In addition, inspiring 
repeat HIV testing(29), ‘opt out’ testing (30) and 
self-HIV testing(31)  can close the gap in DHD in 
Ethiopia and other low-income countries. 
To improve uptake of ART, effective linking 
strategies to care, revising eligibility criteria for 
ART and retaining patients in care help to step up 
from diagnosis to successful treatment(32). For 
example, immediate or same day ART initiation 
after diagnosis was found to be an effective linking 
strategy in resource-limited settings (33). 
Community distribution of ART is also another 
effective innovation for ART delivery as 
demonstrated by studies elsewhere (27). For 
countries with civil unrest or other humanitarian 
disasters, Médicins Sans Frontières (MSF) 
introduced a new approach called “runaway packs” 
that enables individuals to pick up their 
medications to be used for a long duration (34).  
To improve the goal of virological 
suppression, strategies that heighten treatment 
effectiveness such as adherence clubs (2), 
treatment simplification to single dose 
combinations (35) and access to viral load testing 
(27) should be considered. Peter and 
colleagues(36) strongly suggested the need for 
scaling up of viral load testing should HIV 
treatment and virological suppression goals be 
attained. Ethiopia should also learn about the 
rollout of GenXpert instruments for HIV viral load 
and the use of drones for early infant diagnosis 
from Kenya, Malawi and Zimbabwe (27).  
Overall, the 90-90-90 UNAIDS targets is 
an ambitious initiative and the current 
performance—35-65-66—seems too high to meet 
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the coverage target for Ethiopia. This underscores 
the need for concreted efforts to implement the 
aforementioned innovative strategies and effective 
programs. In addition, it also depends on the 
commitment of funding organizations and political 
stakeholders (37). The lack of sufficient funds and 
human resources to deliver ART for HIV infected 
people, together with the raising ART drug 
resistance, will make the success of the goal to halt 
AIDS by 2030 very difficult(38). However, 
Ethiopia would use Health Extension Workers as 
potential human resources for the success of 90-90-
90 targets. Additionally, to curb the scarcity of 
human resources for health, Ethiopia is addressing 
this through decentralization, task shifting and 
deployment of Health Development Army. The 
impact of community-based treatment for 
improving HIV care retention, ART adherence and 
viral suppression has been supported by previous 
studies(39). 
This retrospective study has several 
limitations. The real number of individuals infected 
with HIV or persons who have been diagnosed 
with HIV cannot be obtained or estimated from a 
routinely collected programmatic data. 
Immunologic, clinical and treatment successes 
might not show the actual viral suppression as 
stated by Rutherford and colleagues(40). However, 
this could be a valid surrogate for resource-
constrained HIV burden countries where Plasma 
HIV-1 RNA is not routinely performed.  JUTH is 
found in Oromia Region where the overall regional 
HIV prevalence was 1%,  and the findings from 
this setting may not represent other regional states 
with high HIV prevalence such as Gambella (6.5%) 
(11). Measuring the success rate of UNAIDS 90-
90-90 targets has its own limitations. Comparisons 
over time and space may be misleading because of 
the introduction of variety of HIV programs such 
as “treat all”, testing and linkage and seek-test-
treat-succeed model (40). HIV infected patients 
coming for care at lower viral counts were much 
less likely to commence ART than patients 
presenting at higher viral counts despite that all are 
eligible, and this will lead to selection bias (41).  
In conclusion, of the goal 90-90-90 set by 
the UNAIDS, Ethiopia achieved an estimated 
percentage of 35-65-66. Of a particular concern is 
that DHD and discontinuation from ART are found 
high for females compared to males. In addition, 
immunological, clinical and treatment failures rates 
are higher for females that seek special attention in 
each series of HIV care continuum. Because the 
current system/infrastructure has not been able to 
support the attainment of UNAIDS targets, we 
recommend strengthening or establishing the 
following programs to hit the targets: implementing 
additional and rigorous innovative methods, test-
and-treat strategy, community-based ART 
distribution, strategies during conflict zones 
including runaway packs, and GenXpert for HIV 
viral load testing in areas where there is shortage of 
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